Roivant Sciences’ $200 Million Common Shares Offering

Davis Polk & Wardwell and Conyers Dill & Pearman advised Roivant Sciences Ltd. on the offering. Cooley advised Immunovant on the transaction.Roivant Sciences Ltd. (Nasdaq:ROIV) announced a…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Leila Ahmed

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here